Immuron Share Price and Company Fundamentals

-0.015 (-11.111%)
52 week
0.093 - 0.28

Last traded: Last Friday at 5:10 AM

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

Key Metrics

PE ratio


PB ratio


Dividend yield



Market cap


Enterprise value


Company profile

Primary activitiesImmuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans relating to gastrointestinal health, liver diseases such as fatty liver/NASH and infectious diseases such as Clostridium diffi
Industry / SectorBiotechnology / Healthcare
Mailing address25-37 Chapman Street Unit 10 Blackburn North Carlton VIC 3130 Australia
Phone / Fax61 3 9824 5254 / 61 3 9822 7735


Immuron does not pay dividends.

Company Executives

As of Jan 2022, following are the company executives and directors listed on Immuron.

NameTitleAgeTotal Pay
Dr. Jerry Kanellos Ph.D.CEO & COO60372.52k
Mr. Phillip Allen HainsCFO & Company Sec.62
Mr. David LyonHead of Marketing
Dr. Dan Ruben PeresChief Medical Officer45

Profitability and management effectiveness

Profit margin


Operating margin


Return on assets


Return on equity


Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Immuron is and its enterprise value is .

The IMC's stocks Beta value is 1.87 making it 87% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Immuron (IMC)

Immuron (ASX:IMC) Frequently Asked Questions

1. What is Immuron's Stock Symbol?

Immuron trades on ASX under the ticker symbol "IMC".

2. What is Immuron's stock price today?

One share of IMC stock can currently be purchased for approximately $0.12.

3. How can I contact Immuron?

Immuron's mailing address is 25-37 Chapman Street Unit 10 Blackburn North Carlton VIC 3130 Australia. The company can be reached via phone at 61 3 9824 5254.

4. What is Immuron's official website?

The official website of Immuron is

5. Which share registry manages Immuron's stock?

Immuron's stock is managed by AUTOMIC REGISTRY SERVICES.